TNGX — Tango Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819133 ·
Last close
$22.11
Market Cap
$3.75B
52W High
$34.39
52W Low
$7.69
ADV30
4,052,487
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -78,116,000 | -68,394,000 | 1,033,460,000 | 86,835,000 | 53,287,000 |
| Jun 2026 | 0 | — | -59,785,000 | -55,341,000 | 1,073,880,000 | 345,558,000 | 49,348,000 |
| Mar 2026 | 0 | — | -48,769,000 | -45,514,000 | 435,792,000 | 157,828,000 | 44,286,000 |
| Dec 2025 | 0 | — | -41,864,000 | -38,749,000 | 398,690,000 | 112,279,000 | 52,511,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-150,087,000
Investing CF
$-796,037,000
Financing CF
$974,193,000
CapEx
$-1,048,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-772,401,000
Inventory
—
Receivables
—
ST Investments
$890,668,000
EBIT TTM
$-228,534,000
Pretax Income TTM
$-208,051,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-226,748,000
Free Cash Flow
$-80,177,376
Enterprise Value
$3,374,782,464
Total Cash
$977,502,976
Total Debt
$31,179,000
Shares Out
169,455,160
Trailing EPS
$-1.38
Book Value
$5.79
ROE
-36.5%
ROA
-23.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,384,000 | -111,289,000 | -101,594,000 | 398,690,000 | 52,511,000 | 346,179,000 | -138,886,000 |
| Dec 2024 | 42,069,000 | -145,595,000 | -130,302,000 | 316,492,000 | 116,975,000 | 199,517,000 | -131,501,000 |
| Dec 2023 | 36,527,000 | -114,173,000 | -101,744,000 | 402,567,000 | 149,459,000 | 253,108,000 | -117,982,000 |
| Dec 2022 | 24,860,000 | -111,071,000 | -108,176,000 | 436,470,000 | 186,994,000 | 249,476,000 | -109,080,000 |
TTM Snapshot
Revenues TTM
$53,811,000
NetIncome TTM
$-123,720,000
OpCashFlow TTM
—
Assets (Latest)
$1,073,880,000
Forward EPS
$-1.80
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $27.00 · spot: $21.89 · call volume: 1,879 · put volume: 3,725Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | $3.81B | $38.78 | — |
| OGN | Organon & Co. | $3.65B | $13.90 | — |
| ABCL | AbCellera Biologics Inc. | $3.60B | $11.03 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $3.90B | $19.15 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
News headlines (Yahoo Finance, 1h cache)
A $52 Billion Fund Bought These 3 Stocks
2026-11-14 11:56 · Yahoo
Tango Therapeutics Stock Has The Bull Case Changed After JPMorgan Backing
2026-11-12 06:09 · Yahoo
Erasca Stock In Focus As Combination Trial Begins
2026-11-12 03:13 · Yahoo
JPMorgan highlights stock on Analyst Focus List after 3Q results
2026-11-11 17:15 · Yahoo
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
2026-11-09 12:00 · Yahoo
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
2026-11-04 13:30 · Yahoo
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
2026-11-03 12:00 · Yahoo
Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus
2026-10-28 17:11 · Yahoo
Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?
2026-10-28 13:16 · Yahoo
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
2026-10-23 20:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.